BRPI0721113A2 - Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios

Info

Publication number
BRPI0721113A2
BRPI0721113A2 BRPI0721113-9A2A BRPI0721113A BRPI0721113A2 BR PI0721113 A2 BRPI0721113 A2 BR PI0721113A2 BR PI0721113 A BRPI0721113 A BR PI0721113A BR PI0721113 A2 BRPI0721113 A2 BR PI0721113A2
Authority
BR
Brazil
Prior art keywords
compound
represent
independently
treat
conditions
Prior art date
Application number
BRPI0721113-9A2A
Other languages
English (en)
Inventor
Jakob Felding
Simon Feldbaek Nielsen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of BRPI0721113A2 publication Critical patent/BRPI0721113A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0721113-9A2A 2006-12-22 2007-12-21 Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios BRPI0721113A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87168906P 2006-12-22 2006-12-22
US94547007P 2007-06-21 2007-06-21
PCT/DK2007/000564 WO2008077404A1 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as pde4 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0721113A2 true BRPI0721113A2 (pt) 2014-10-07

Family

ID=39156588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721113-9A2A BRPI0721113A2 (pt) 2006-12-22 2007-12-21 Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios

Country Status (23)

Country Link
US (3) US8148537B2 (pt)
EP (1) EP2125736B1 (pt)
JP (1) JP5342451B2 (pt)
KR (1) KR101507717B1 (pt)
AT (1) ATE503742T1 (pt)
AU (1) AU2007336538B2 (pt)
BR (1) BRPI0721113A2 (pt)
CA (1) CA2673370C (pt)
CR (1) CR10877A (pt)
CY (1) CY1111596T1 (pt)
DE (1) DE602007013617D1 (pt)
DK (1) DK2125736T3 (pt)
GT (1) GT200900172A (pt)
HR (1) HRP20110464T1 (pt)
IL (1) IL199383A (pt)
MX (1) MX2009006593A (pt)
MY (1) MY146022A (pt)
NO (1) NO20092372L (pt)
NZ (1) NZ577863A (pt)
PL (1) PL2125736T3 (pt)
PT (1) PT2125736E (pt)
RU (1) RU2493149C2 (pt)
WO (1) WO2008077404A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322776A1 (en) 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
BR112012015449B1 (pt) 2009-12-22 2021-09-28 Leo Pharma A/S Suspensão de monoidrato de calcipotriol, e, processo para preparar nanocristais de monoidrato de calcipotriol
CN102770121B (zh) 2009-12-22 2014-10-15 利奥制药有限公司 包含溶剂混合物和维生素d衍生物或类似物的药物组合物
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
US9855285B2 (en) * 2012-11-30 2018-01-02 Leo Pharma A/S Method of inhibiting the expression of IL-22 in activated T-cells
WO2014096018A1 (en) * 2012-12-19 2014-06-26 Leo Pharma A/S Methods for the preparation of substituted acetophenones
FI3587400T3 (fi) * 2013-10-22 2024-06-20 Chiesi Farm Spa Menetelmä pde4:n estäjän valmistamiseksi
RU2697251C2 (ru) * 2014-06-23 2019-08-13 Лео Фарма А/С Способы получения 1, 3-бензодиоксольных гетероциклических соединений
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN114085234B (zh) 2015-12-18 2024-12-17 联合疗法公司 用于制备1,3-苯并间二氧杂环戊烯杂环化合物的方法
KR101702648B1 (ko) * 2016-05-10 2017-02-03 주식회사 엑티브온 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물
KR102676384B1 (ko) 2017-06-20 2024-06-20 유니온 테라퓨틱스 에이/에스 1,3-벤조디옥솔 헤테로시클릭 화합물의 제조방법
EP3838967A1 (en) 2019-12-16 2021-06-23 Spago Nanomedical AB Immobilization of phenolic compounds
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (pt) * 1992-12-23 1995-11-21 Celltech Ltd
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
AU705690B2 (en) * 1995-05-19 1999-05-27 Kyowa Hakko Kogyo Co. Ltd. Oxygen-containing heterocyclic compounds
WO1998022455A1 (en) * 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
HRP20050905A2 (hr) * 2003-03-17 2006-04-30 Kyowa Hakko Kogyo Co. Terapeutski i/ili preventivni agensi za kronične kožne bolesti
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
RU2493149C2 (ru) 2013-09-20
JP2010513334A (ja) 2010-04-30
HK1135392A1 (en) 2010-06-04
JP5342451B2 (ja) 2013-11-13
KR20090098990A (ko) 2009-09-18
EP2125736A1 (en) 2009-12-02
MX2009006593A (es) 2009-07-02
NZ577863A (en) 2012-04-27
CR10877A (es) 2009-07-10
US20130012716A1 (en) 2013-01-10
PT2125736E (pt) 2011-07-01
IL199383A (en) 2015-02-26
KR101507717B1 (ko) 2015-04-08
CY1111596T1 (el) 2015-10-07
ATE503742T1 (de) 2011-04-15
RU2009128191A (ru) 2011-01-27
CA2673370C (en) 2015-11-17
MY146022A (en) 2012-06-15
DE602007013617D1 (de) 2011-05-12
CA2673370A1 (en) 2008-07-03
PL2125736T3 (pl) 2011-09-30
DK2125736T3 (da) 2011-07-11
US8148537B2 (en) 2012-04-03
AU2007336538B2 (en) 2012-04-05
US8497380B2 (en) 2013-07-30
GT200900172A (es) 2011-10-05
US20100035908A1 (en) 2010-02-11
WO2008077404A1 (en) 2008-07-03
NO20092372L (no) 2009-07-14
EP2125736B1 (en) 2011-03-30
HRP20110464T1 (hr) 2011-07-31
US20120165539A1 (en) 2012-06-28
US8324394B2 (en) 2012-12-04
AU2007336538A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
CR10877A (es) Acetofenonas sustituidas utiles en terapia
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
WO2007071632A3 (en) 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
HUP0303164A2 (hu) Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények
GB0612423D0 (en) Therapeutic agents
AR063211A1 (es) Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide.
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
EA200700099A1 (ru) Производные пиридина
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
ECSP034534A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
UY28333A1 (es) Inhibidores de caspasa y sus usos.
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
UA96783C2 (ru) Замещенные метилфенилкетоны, пригодные для использования как ингибиторы pde4

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL